Product Description
Mechanisms of Action: CaSR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Other|Osteoporosis
Phase 1: Osteoporosis|Stem Cell Transplant|Bone Marrow Transplantation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Ronacaleret | P1 |
Completed |
Stem Cell Transplant |
2013-04-02 |
|
NCT01466335 | P1 |
Completed |
Bone Marrow Transplantation|Stem Cell Transplant |
2012-03-05 |
|
2007-001477-29 | P2 |
Terminated |
Unknown |
2009-01-10 |
|
Study CR9108963 | P2 |
Terminated |
Osteoporosis |
2008-12-26 |